In the News

Analysts Project Retatrutide Could Reach $30 Billion in Sales by 2031

January 8, 2026

PharmExec

Share this article

Our Take

This is the clearest signal yet of how seriously the industry is taking retatrutide. Clarivate — a respected analytics firm whose annual "Drugs to Watch" report is closely followed — projects it will out-earn every other drug on its 2031 watch list by a wide margin. That's not hype from a seller; it's a forecast from analysts with no stake in the drug.

Context note: these are projections, not results. They assume approval and a 2028 launch that hasn't happened yet, and the same report flags real risks — FDA uncertainty, pricing reform, and payer coverage limits — that could pull the numbers down.

What the report projects

Retatrutide is projected to generate $30 billion in sales in 2031 — split between $10 billion in obesity and $20 billion in diabetes.
That's far ahead of every other drug on Clarivate's list: no other watch-list drug is projected to exceed $2 billion that year.
Lilly's oral GLP-1 pill orforglipron is projected at $16 billion in 2031.
The global obesity drug market is forecast to reach $150 billion by 2035 (Morgan Stanley).
U.S. GLP-1 prescriptions for overweight or obese adults rose 586.7% from 2019 to 2024.
Clarivate projects retatrutide will be ready for launch around 2028.

Why retatrutide stands out

Clarivate's analysts describe retatrutide and orforglipron as the next generation of metabolic therapies — pointing to the triple-hormone mechanism that drives larger weight loss and potential uses reaching beyond obesity into areas like liver and kidney disease. Retatrutide's projected $30 billion is what happens when a drug is expected to compete in both the obesity and diabetes markets at once.

The report is candid about the flip side, too: the industry still has to solve pricing negotiations, payer coverage limits, supply constraints, and muscle-mass preservation during rapid weight loss. Those are the variables that decide whether a projection like this is met or missed.

Where this fits

Most of this hub covers what retatrutide does in trials. This one covers what it's worth — the commercial stakes that explain why the drug generates so much attention, and so much premature demand, before it's even approved. It's the market context behind the science.

Retatrutide remains investigational. A $30 billion projection is a forecast, not a fact, and depends on approvals and market conditions that are still years away.

Disclaimer

Retatrutide is an investigational drug. It is not approved by the FDA and is not legally available outside clinical trials. This page is informational and is not medical advice or an offer to sell.

Register your interest in Retatrutide

Retatrutide is currently not available, but once it is approved, you’ll be the first to get notified. Sign up now and stay informed.

Simple one-time sign-up

Early access to availability updates

Exclusive status among the first users

Advantage over non-registered users

Retatrutide investigational weight loss medication prescription bottle with 28.7% efficacy data